Most pharma R&D organisations are defined and measured by how well they deliver new product innovation, which is often a high risk, high return endeavour. Yet such companies almost always have a second, highly important and sometimes underappreciated role: creating value from on market products.
This article, published in MedNous, analyses the performance of these companies in the context of new product and on-market product innovation, and demonstrates that success in on-market product innovation provides companies with the profit margins to additionally invest in new product innovation.
© 2023 Evernow Publishing Ltd
Reprinted with permission from MedNous, April 2023 (www.mednous.com)
For further insights into Europe’s MidPharmas, we examine this microcosm of the global industry and analyse how these companies thrive in our latest European MidPharma Report.
